Literature DB >> 34390446

Phenotypes of STAT3 gain-of-function variant related to disruptive regulation of CXCL8/STAT3, KIT/STAT3, and IL-2/CD25/Treg axes.

Lia Furlaneto Marega1, Janine Schincariol Sabino1, Marcus Vinicius Pedroni1, Marcelo Teocchi1, Carolina Lanaro2, Dulcinéia Martins de Albuquerque2, Irene Pereira Dos Santos3, Fernando Ferreira Costa2, Maria Marluce Dos Santos Vilela4.   

Abstract

STAT3 is a cytokine-signaling transcription factor critical for gene regulation. Gain-of-function (GOF) mutations in STAT3 are associated with lymphoproliferation, autoimmune cytopenias, increased susceptibility to infection, early-onset solid-organ autoimmunity, short stature, and eczema. We studied the JAK/STAT signaling pathway gene expression and the cytokine profile in two families carrying STAT3-GOF variants to shed light on the STAT3-GOF-associated variable expressivity, including the identification of disease markers. Considering 92 target genes, KIT and IL2RA were downregulated only in patients with high clinical penetrance, while CXCL8 was markedly downregulated for all of them. Unlike previous studies, SOCS3-a STAT3 inhibitor-was not upregulated in patients. In addition, low levels of IL-2 and a reduced numbers of Tregs cells were strikingly prevalent in patients. This study shows a disruptive role of STAT3-GOF variants in the regulatory axis activities CXCL8/STAT3, KIT/STAT3, IL2/CD25/Treg, which, by slightly different mechanisms, underlie the broad clinical spectrum seen in the studied patients. In addition, we suggest the investigation of CXCL8 as a biomarker for identifying STAT3-GOF mutation.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gene expression regulation; Hypogammaglobulinemia; Inborn errors of immunity; Phosphorylation

Mesh:

Substances:

Year:  2021        PMID: 34390446     DOI: 10.1007/s12026-021-09225-0

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  45 in total

1.  Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

Authors:  Emma M Haapaniemi; Meri Kaustio; Hanna L M Rajala; Arjan J van Adrichem; Leena Kainulainen; Virpi Glumoff; Rainer Doffinger; Heikki Kuusanmäki; Tarja Heiskanen-Kosma; Luca Trotta; Samuel Chiang; Petri Kulmala; Samuli Eldfors; Riku Katainen; Sanna Siitonen; Marja-Liisa Karjalainen-Lindsberg; Panu E Kovanen; Timo Otonkoski; Kimmo Porkka; Kaarina Heiskanen; Arno Hänninen; Yenan T Bryceson; Raija Uusitalo-Seppälä; Janna Saarela; Mikko Seppänen; Satu Mustjoki; Juha Kere
Journal:  Blood       Date:  2014-10-27       Impact factor: 22.113

Review 2.  STAT3 signaling: anticancer strategies and challenges.

Authors:  Paul A Johnston; Jennifer R Grandis
Journal:  Mol Interv       Date:  2011-02

3.  Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity.

Authors:  Sabine Jägle; Maximilian Heeg; Sarah Grün; Anne Rensing-Ehl; Maria Elena Maccari; Christian Klemann; Neil Jones; Kai Lehmberg; Claudia Bettoni; Klaus Warnatz; Bodo Grimbacher; Ariane Biebl; Uwe Schauer; Rosie Hague; Olaf Neth; Andrea Mauracher; Jana Pachlopnik Schmid; Alexandre Fabre; Larysa Kostyuchenko; Marita Führer; Myriam Ricarda Lorenz; Klaus Schwarz; Jan Rohr; Stephan Ehl
Journal:  Clin Immunol       Date:  2019-11-23       Impact factor: 3.969

Review 4.  Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.

Authors:  Kodappully Sivaraman Siveen; Sakshi Sikka; Rohit Surana; Xiaoyun Dai; Jingwen Zhang; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Biochim Biophys Acta       Date:  2014-01-02

5.  Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review.

Authors:  Alexandre Fabre; Sarah Marchal; Vincent Barlogis; Bernard Mari; Pascal Barbry; Pierre-Simon Rohrlich; Lisa R Forbes; Tiphanie P Vogel; Lisa Giovannini-Chami
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-27

6.  Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.

Authors:  Joshua D Milner; Tiphanie P Vogel; Lisa Forbes; Chi A Ma; Asbjørg Stray-Pedersen; Julie E Niemela; Jonathan J Lyons; Karin R Engelhardt; Yu Zhang; Nermina Topcagic; Elisha D O Roberson; Helen Matthews; James W Verbsky; Trivikram Dasu; Alexander Vargas-Hernandez; Nidhy Varghese; Kenneth L McClain; Lina B Karam; Karen Nahmod; George Makedonas; Emily M Mace; Hanne S Sorte; Gøri Perminow; V Koneti Rao; Michael P O'Connell; Susan Price; Helen C Su; Morgan Butrick; Joshua McElwee; Jason D Hughes; Joseph Willet; David Swan; Yaobo Xu; Mauro Santibanez-Koref; Voytek Slowik; Darrell L Dinwiddie; Christina E Ciaccio; Carol J Saunders; Seth Septer; Stephen F Kingsmore; Andrew J White; Andrew J Cant; Sophie Hambleton; Megan A Cooper
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

Review 7.  The Ying and Yang of STAT3 in Human Disease.

Authors:  Tiphanie P Vogel; Joshua D Milner; Megan A Cooper
Journal:  J Clin Immunol       Date:  2015-08-18       Impact factor: 8.317

Review 8.  Signal transducer and activator of transcription 3: a year in review.

Authors:  Lisa R Forbes; Josh Milner; Elie Haddad
Journal:  Curr Opin Hematol       Date:  2016-01       Impact factor: 3.284

9.  Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges.

Authors:  Sundas Arshad; Muhammad Naveed; Mahad Ullia; Khadija Javed; Ayesha Butt; Masooma Khawar; Fazeeha Amjad
Journal:  Genet Mol Biol       Date:  2020-02-10       Impact factor: 1.771

Review 10.  Signal Transducer and Activator of Transcription 3 Control of Human T and B Cell Responses.

Authors:  Elissa K Deenick; Simon J Pelham; Alisa Kane; Cindy S Ma
Journal:  Front Immunol       Date:  2018-02-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.